Agios Pharmaceuticals vs Cytokinetics
AGIO and CYTK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGIO and CYTK compare
Agios Pharmaceuticals is the larger company, worth 233 times as much as Cytokinetics ($1.8B against $7.8M).
Agios Pharmaceuticals grew revenue faster over the last twelve months (141% versus −21.1% for Cytokinetics).
Agios Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −418% compared with −1321% at Cytokinetics.
Agios Pharmaceuticals scores higher on the StockData Score (12 against 4 for Cytokinetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGIO | CYTK |
|---|---|---|
| Size and price | ||
| Market cap | $1.8B | $7.8M |
| Share price | $30.55 | $62.99 |
| Change, 1 year | −27.2% | 1.6% |
| Change, 5 years | −33.1% | 53.3% |
| Beta (5Y) | 1.37 | 0.82 |
| Employees | 539 | 673 |
| StockData Score | ||
| Total score | 12 (better) | 4 |
| Valuation score | 1 | 1 |
| Growth score | 3 (better) | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 18.5× | 0.1× (better) |
| P/B | 1.8× | – |
| FCF yield | −20.0% (better) | −7408% |
| Fair value | $28.38 | – |
| Margin of safety | −7.7% | – |
| Growth | ||
| Revenue growth (TTM) | 141% (better) | −21.1% |
| Revenue growth, 5Y average | – | 9.5% |
| Net income growth (TTM) | −163% | – |
| EPS growth (TTM) | −163% | – |
| Profitability | ||
| Gross margin | 92.0% | – |
| Operating margin | −467% (better) | −1046% |
| Net margin | −418% (better) | −1321% |
| FCF margin | −371% (better) | −858% |
| Return on equity | −34.3% | – |
| Return on invested capital | −759% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 10.22 (better) | 6.66 |
| Altman Z-score | 11.74 (better) | −3.37 |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 111% | 115% |
| Held by insiders | 1.1% | 0.68% |
| Insider net buying, 12 months | −$4.6M (better) | −$50.6M |
| Short interest, % of float | 11.9% | 14.0% |
Go deeper
- AGIO stock overview
- AGIO income statement
- AGIO valuation and score
- CYTK stock overview
- CYTK income statement
- CYTK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.